CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Boutolleau D

    Mutations:

    Mutant Gene Virus Reference
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    V33A UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A36V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    E75G UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L122P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    R129H UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A221V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    N446S UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    450-453del UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A464V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    H509N UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V582M UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G649D UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    H698Q UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    C721Y UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A788T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V793P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    Y806T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T811P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A812G UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G813A UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A820Q UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L38M UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L562F UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A659V UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V673I UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S7F UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    L14F UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    R112H UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    P132L UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    S133P UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    V171I UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    A238T UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    S249C UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    Q449R UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    M615V UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230